3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Your Basket's Financial Footprint
This basket's $14.60B total market cap is heavily anchored by a single large-cap holding, representing roughly 67.7% of the total, giving it a large-cap dominated profile.
- Large-cap dominance suggests generally lower volatility and returns aligned with broad market trends, reducing idiosyncratic risk.
- Suitable as a core holding, providing steady sector exposure rather than a speculative growth position.
- Expect steadier long-term appreciation; unlikely to deliver rapid, short-term explosive gains.
HUMA: $319.67M
CLGN: $30.14M
ORGO: $516.31M
- Other
About This Group of Stocks
Our Expert Thinking
We've identified companies at the intersection of 3D printing technology and biology that are creating functional human tissues. This emerging field targets massive opportunities in transplantation, personalized medicine, and pharmaceutical testing – potentially solving critical healthcare challenges like organ shortages.
What You Need to Know
This is a high-risk, high-reward investment focused on early-stage medical technology. Recent breakthroughs in creating vascular networks within printed tissues represent a critical advancement that could accelerate development and adoption. Consider this a satellite holding in a diversified portfolio.
Why These Stocks
We've carefully selected companies across the entire value chain – from pure-play tissue engineering firms to specialized 3D printer manufacturers and suppliers of critical biomaterials and technologies. This approach provides comprehensive exposure to this promising but still-developing field.
Why You'll Want to Watch These Stocks
Breakthrough Technology Moment
Recent advances in creating vascular networks within printed tissues represent a critical milestone that could accelerate development of larger, more complex organs and tissues.
Solving a $450B+ Problem
The global organ shortage affects millions of patients. These companies are pioneering solutions that could transform transplantation medicine and save countless lives.
Faster, Better Drug Development
Bioprinted human tissues provide pharmaceutical companies with more accurate models for drug testing, potentially reducing development costs and bringing new treatments to market sooner.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Antiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Streaming Power Dynamics Explained | Content Wars
The resolution of the content dispute between Disney and Google's YouTube TV highlights the critical interdependence of content creators and distributors. This dynamic creates an investment opportunity in companies that are central to the streaming ecosystem, from content production to platform delivery.
Jeep Hybrid Recall Overview: Market Shift Analysis
Stellantis is recalling nearly 113,000 Jeep plug-in hybrids because of a serious engine defect, creating potential investment opportunities. This theme focuses on competing automakers and aftermarket parts suppliers that may benefit from a shift in consumer confidence and repair needs.